MX2009009132A - Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. - Google Patents
Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.Info
- Publication number
- MX2009009132A MX2009009132A MX2009009132A MX2009009132A MX2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A
- Authority
- MX
- Mexico
- Prior art keywords
- naltrexone
- buprenorphine
- medicinal compositions
- improved medicinal
- dosage form
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 5
- 229960001736 buprenorphine Drugs 0.000 title abstract 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 5
- 229960003086 naltrexone Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000202 analgesic effect Effects 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 210000004207 dermis Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición analgésica, en forma de dosificación de unidad parenteral o en una forma de dosificación de unidad adecuada para liberación mediante la dermis o mucosa, comprende buprenorfina y una cantidad de naltrexona de modo que la relación en peso de buprenorfina a naltrexona liberada a o que alcanza el plasma de un paciente esté en el rango de 100:1 a 5000:1. La acción analgésica de la buprenorfina es potencializada por la dosis baja de naltrexona. También se proporciona un método de tratamiento de dolor y el uso de buprenorfina y naltrexona para la fabricación de un medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0703966A GB2447014A (en) | 2007-03-01 | 2007-03-01 | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| PCT/GB2008/000521 WO2008104735A1 (en) | 2007-03-01 | 2008-02-15 | Improved medicinal compositions comprising buprenorphine and naltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009132A true MX2009009132A (es) | 2009-09-03 |
Family
ID=37965733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009132A MX2009009132A (es) | 2007-03-01 | 2008-02-15 | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8912211B2 (es) |
| EP (1) | EP2125019B1 (es) |
| JP (1) | JP5577101B2 (es) |
| KR (1) | KR20090115861A (es) |
| CN (1) | CN101622014A (es) |
| AR (1) | AR065580A1 (es) |
| AU (1) | AU2008220620A1 (es) |
| BR (1) | BRPI0807902A2 (es) |
| CA (1) | CA2678481C (es) |
| CL (1) | CL2008000608A1 (es) |
| DK (1) | DK2125019T3 (es) |
| ES (1) | ES2475734T3 (es) |
| GB (1) | GB2447014A (es) |
| HR (1) | HRP20140592T1 (es) |
| MX (1) | MX2009009132A (es) |
| PE (1) | PE20081799A1 (es) |
| PL (1) | PL2125019T3 (es) |
| PT (1) | PT2125019E (es) |
| TW (1) | TW200836737A (es) |
| WO (1) | WO2008104735A1 (es) |
| ZA (1) | ZA200905689B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9095548B2 (en) | 2010-04-29 | 2015-08-04 | Allodynic Therapeutics, Llc | Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain |
| US9205081B2 (en) | 2010-04-29 | 2015-12-08 | Allodynic Therapeutics, Llc | Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain |
| JP5977240B2 (ja) * | 2010-09-21 | 2016-08-24 | パーデュー、ファーマ、リミテッド、パートナーシップ | ブプレノルフィン類似体 |
| WO2014160077A1 (en) * | 2013-03-13 | 2014-10-02 | Allodynic Therapeutics, Llc | Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor |
| ES2703623T3 (es) * | 2013-06-28 | 2019-03-11 | Purdue Pharma Lp | Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides |
| JP2016529328A (ja) | 2013-09-10 | 2016-09-23 | インシス・ファーマ・インコーポレーテッド | 舌下ブプレノルフィンスプレー |
| US9839611B2 (en) | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US9867818B2 (en) | 2013-09-10 | 2018-01-16 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US9918981B2 (en) | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10617686B2 (en) | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| EP3177146A4 (en) | 2014-07-08 | 2018-01-03 | Insys Pharma, Inc. | Sublingual naloxone spray |
| WO2018081792A2 (en) | 2016-10-31 | 2018-05-03 | Allodynic Therapeutics, Llc | Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia |
| US11752143B2 (en) | 2020-12-31 | 2023-09-12 | Soin Therapeutics Llc | Methods of using low dose naltrexone to treat chronic pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US572149A (en) * | 1896-12-01 | Tobacco-cutting machine | ||
| GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US5272149A (en) | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| JP2001526229A (ja) * | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク，エス．エイ． | オピオイド投薬剤形の乱用を防止する方法 |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
-
2007
- 2007-03-01 GB GB0703966A patent/GB2447014A/en not_active Withdrawn
-
2008
- 2008-02-15 BR BRPI0807902-1A2A patent/BRPI0807902A2/pt not_active IP Right Cessation
- 2008-02-15 MX MX2009009132A patent/MX2009009132A/es active IP Right Grant
- 2008-02-15 EP EP08709412.4A patent/EP2125019B1/en not_active Not-in-force
- 2008-02-15 PT PT87094124T patent/PT2125019E/pt unknown
- 2008-02-15 CA CA2678481A patent/CA2678481C/en not_active Expired - Fee Related
- 2008-02-15 AU AU2008220620A patent/AU2008220620A1/en not_active Abandoned
- 2008-02-15 KR KR1020097018309A patent/KR20090115861A/ko active Search and Examination
- 2008-02-15 PL PL08709412T patent/PL2125019T3/pl unknown
- 2008-02-15 CN CN200880006857A patent/CN101622014A/zh active Pending
- 2008-02-15 US US12/529,173 patent/US8912211B2/en not_active Expired - Fee Related
- 2008-02-15 JP JP2009551253A patent/JP5577101B2/ja not_active Expired - Fee Related
- 2008-02-15 DK DK08709412.4T patent/DK2125019T3/da active
- 2008-02-15 ES ES08709412.4T patent/ES2475734T3/es active Active
- 2008-02-15 WO PCT/GB2008/000521 patent/WO2008104735A1/en active Application Filing
- 2008-02-27 TW TW097106771A patent/TW200836737A/zh unknown
- 2008-02-28 CL CL200800608A patent/CL2008000608A1/es unknown
- 2008-02-29 PE PE2008000410A patent/PE20081799A1/es not_active Application Discontinuation
- 2008-02-29 AR ARP080100881A patent/AR065580A1/es unknown
-
2009
- 2009-08-17 ZA ZA2009/05689A patent/ZA200905689B/en unknown
-
2014
- 2014-06-24 HR HRP20140592AT patent/HRP20140592T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008104735A1 (en) | 2008-09-04 |
| CN101622014A (zh) | 2010-01-06 |
| DK2125019T3 (da) | 2014-06-30 |
| GB0703966D0 (en) | 2007-04-11 |
| PT2125019E (pt) | 2014-07-11 |
| TW200836737A (en) | 2008-09-16 |
| CA2678481A1 (en) | 2008-09-04 |
| EP2125019B1 (en) | 2014-04-09 |
| ES2475734T3 (es) | 2014-07-11 |
| US8912211B2 (en) | 2014-12-16 |
| PL2125019T3 (pl) | 2014-08-29 |
| ZA200905689B (en) | 2010-10-27 |
| AU2008220620A1 (en) | 2008-09-04 |
| EP2125019A1 (en) | 2009-12-02 |
| CL2008000608A1 (es) | 2008-10-03 |
| GB2447014A (en) | 2008-09-03 |
| PE20081799A1 (es) | 2008-12-18 |
| US20100120812A1 (en) | 2010-05-13 |
| HRP20140592T1 (hr) | 2014-09-12 |
| JP5577101B2 (ja) | 2014-08-20 |
| JP2010520183A (ja) | 2010-06-10 |
| AR065580A1 (es) | 2009-06-17 |
| CA2678481C (en) | 2014-11-18 |
| KR20090115861A (ko) | 2009-11-09 |
| BRPI0807902A2 (pt) | 2014-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1139871A1 (en) | Improvements in and relating to medicinal compositions | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| JP2010520186A5 (es) | ||
| MX2009009133A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona. | |
| JP2010520183A5 (es) | ||
| MX2009009134A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno. | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| IL203747A (en) | Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| HUP0203588A2 (hu) | Fájdalomcsillapító hatású gyógyszerkészítmények és alkalmazásuk | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| IL196425A (en) | Dosage unit for oral administration containing ibuprofen and pamotidine | |
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| NZ617397A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| WO2008106689A3 (en) | Breakthrough pain management | |
| JP2010520184A5 (es) | ||
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| NZ719087A (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: RB PHARMACEUTICALS LIMITED.* |
|
| FG | Grant or registration |